Department of Gynaecology, Helse Finnmark, Klinikk Hammerfest, Hammerfest, Norway.
BJOG. 2010 Jan;117(1):53-61. doi: 10.1111/j.1471-0528.2009.02435.x.
To compare the impact of 1000 microg of self-administered vaginal misoprostol versus self-administered vaginal placebo on preoperative cervical ripening after 2 weeks of pretreatment with estradiol vaginal tablets in postmenopausal women prior to day-care operative hysteroscopy.
Randomised, double-blind, placebo-controlled sequential trial.
Norwegian university teaching hospital.
Sixty-seven postmenopausal women referred for day-care operative hysteroscopy.
The women were randomised to receive either 1000 microg of self-administered vaginal misoprostol or self-administered vaginal placebo on the evening before day-care operative hysteroscopy. All women had administered a 25-microg vaginal estradiol tablet daily for 14 days prior to the operation.
preoperative cervical dilatation at hysteroscopy.
difference in dilatation at recruitment and before hysteroscopy, number of women who achieved a preoperative cervical dilatation of 5 mm or more, acceptability, complications and adverse effects.
The mean cervical dilatation was 5.7 mm (SD, 1.6 mm) in the misoprostol group and 4.7 mm (SD, 1.5 mm) in the placebo group, the mean difference in cervical dilatation being 1.0 mm (95% CI, 0.2-1.7 mm). Self-administered vaginal misoprostol of 1000 microg at home on the evening before day-care hysteroscopy is safe and highly acceptable, although a small proportion of women experienced lower abdominal pain.
One thousand micrograms of self-administered vaginal misoprostol, 12 hours prior to day-care hysteroscopy, after 14 days of pretreatment with vaginal estradiol, has a significant cervical ripening effect compared with placebo in postmenopausal women.
比较经阴道给予 1000μg 米索前列醇与安慰剂预处理 2 周后对绝经后妇女行日间宫腔镜手术前宫颈成熟的影响。
随机、双盲、安慰剂对照序贯试验。
挪威大学教学医院。
67 例绝经后妇女，日间行宫腔镜手术。
这些妇女随机接受阴道内米索前列醇或安慰剂治疗，均于日间宫腔镜手术前一晚给药。所有妇女在手术前 14 天内每日经阴道给予 25μg 雌激素片。
宫腔镜检查时的术前宫颈扩张程度。
招募时和宫腔镜检查前的扩张程度差异、达到术前宫颈扩张 5mm 或以上的妇女人数、可接受性、并发症和不良反应。
米索前列醇组的平均宫颈扩张度为 5.7mm（标准差，1.6mm），安慰剂组为 4.7mm（标准差，1.5mm），宫颈扩张程度的平均差异为 1.0mm（95%置信区间，0.2-1.7mm）。经阴道给予 1000μg 米索前列醇，在日间宫腔镜手术前一晚自行在家给药是安全且高度可接受的，尽管一小部分妇女出现下腹疼痛。
与安慰剂相比，经阴道给予 1000μg 米索前列醇，在经阴道给予雌激素预处理 14 天后，于日间宫腔镜手术前 12 小时给药，对绝经后妇女有显著的宫颈成熟作用。
